Glucored

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glucored

Property Description
Active Ingredient Gliclazide
Form Oral Tablets (Standard or Modified-Release)
Pharmacological Class Oral Hypoglycemic Agent (OHA); Sulfonylurea
Common Use Managing high blood sugar in Type 2 Diabetes Mellitus
Origin Synthetic

What is Glucored and Its Core Composition?

Glucored is a prescription-only medication primarily used to help manage elevated blood sugar levels associated with Type 2 Diabetes Mellitus. Its therapeutic action is based on the single active ingredient, Gliclazide (INN), a synthetic chemical entity. This monocomponent drug is presented as an oral formulation in the form of solid tablets, which may include modified-release (MR/XL) versions designed for extended drug delivery. The established oral route of administration provides a convenient method for patients to incorporate the active agent necessary for ongoing metabolic control. The use of Gliclazide in managing Type 2 Diabetes is broadly clinically recognized.


Glucored's Pharmacological Class and Differentiation

Glucored is classified as an Oral Hypoglycemic Agent (OHA), belonging specifically to the sulfonylurea group of antidiabetic drugs. Gliclazide is chemically a synthetic compound, categorized as a second-generation sulfonylurea derivative. This classification defines its role as a medication that lowers blood glucose when taken by mouth, distinguishing it from alternative treatments such as injectable insulin preparations.

Gliclazide's profile is often differentiated within its class by its chemical structure, which may contribute to a lower reported risk of certain adverse cardiovascular outcomes compared to some older sulfonylureas.


General Purpose: How Glucored Helps Manage Glucose Homeostasis

The general purpose of Glucored is to help patients achieve and sustain better glucose homeostasis, or stable blood sugar control, critical in managing Type 2 Diabetes. Its core functional principle is acting as an insulin secretagogue, meaning it prompts the pancreas's beta-cells to release more of the body’s own insulin. This action helps regulate glucose.

By stimulating this release, Glucored indirectly facilitates the movement of glucose from the bloodstream into body cells, thereby reducing the concentration of sugar in the blood. This general mechanism is typically utilized as foundational therapy in patients whose blood sugar cannot be managed by diet and exercise alone.

What side effects are possible with Glucored?

Possible side effects and safety information

The safety profile of Gliclazide (Glucored), an oral hypoglycemic agent, is structured around its primary pharmacological effect and officially documented systemic risks. The core safety concern, classified as common, is Hypoglycaemia (low blood sugar), which can range from mild to severe and is inherent to the drug class.

Official Adverse Reaction Groupings

Adverse reactions are formally categorized by System-Organ Classes (SOCs) in regulatory documents, including effects on the Gastrointestinal System, Skin and Subcutaneous Tissues, Hepatobiliary System, and Blood and Lymphatic System.

Frequency Classification Examples of Documented Effects
Common Hypoglycaemia
Uncommon Gastrointestinal disturbances (e.g., nausea, abdominal pain, diarrhea)
Rare/Very Rare Hepatitis, severe blood disorders, severe cutaneous reactions (e.g., Stevens-Johnson syndrome)

Serious Reactions and Safety Constraints

The regulatory profile highlights rare but serious reactions such as severe Hepatitis, severe Blood Disorders (e.g., agranulocytosis), and Severe Cutaneous Adverse Reactions (SCARs). The medication is officially contraindicated in specific patient populations, including those with Severe Renal or Hepatic Insufficiency and during Pregnancy or Lactation. Safety notes also indicate that certain effects, such as transient visual disturbances, may be observed at the start of treatment due to initial blood glucose changes.

Overdose and Emergency Response

The official regulatory profile for Glucored overdose is centered on the risk of inducing severe and prolonged hypoglycemia. This condition is the primary documented clinical manifestation, typically involving distinct symptom clusters.

Documented Overdose Presentations

Symptoms may include adrenergic signs such as excessive sweating, clammy skin, anxiety, and heart palpitations. As glucose levels drop further, neuroglycopenic symptoms emerge, including drowsiness, severe confusion, visual and speech disturbances, and delirium. The most serious outcomes officially documented include loss of consciousness, convulsions, and the potential for temporary or permanent impairment of brain function or death from uncorrected hypoglycemia.

When Immediate Medical Help is Required

Immediate medical treatment or hospitalization is required for any hypoglycemic episode that is classified as severe or prolonged, even if symptoms are temporarily reversed by the immediate intake of sugar or carbohydrates. Due to the sustained effects, official regulatory guidance requires that supportive care, which typically involves glucose administration, may need to be continued for several days under observation to prevent the recurrence of hypoglycemia.

Increased susceptibility to these severe outcomes is noted in the elderly and in patients with documented impaired hepatic or renal function.

Therapeutic Uses of Glucored

Main Uses of Glucored

Glucored is a combination medication used to manage blood sugar levels in adults with type 2 diabetes mellitus. It is typically prescribed when diet, exercise, and treatment with a single oral glucose-lowering agent do not provide adequate glycemic control.

The medication contains two active ingredients that work through different mechanisms to regulate blood glucose:

  • Glibenclamide: A sulfonylurea that stimulates the pancreas to release more insulin.
  • Metformin: A biguanide that improves the body's sensitivity to insulin and reduces the amount of glucose produced by the liver.

Therapeutic Benefits

Improved Glycemic Control

By combining two distinct pharmacological actions, Glucored helps achieve more consistent blood sugar levels throughout the day and night. This synergy often allows for better management of hemoglobin A1c (HbA1c) levels than using either component alone.

Reduction of Post-Meal Glucose Spikes

The glibenclamide component is particularly effective at stimulating insulin secretion in response to food intake, which helps mitigate the sharp rise in blood sugar that occurs after eating.

Enhanced Insulin Sensitivity

The metformin component helps the body use its existing insulin more effectively and decreases the absorption of glucose from the gastrointestinal tract. Unlike some other diabetes medications, it does not typically cause weight gain and may assist in weight maintenance.

Long-Term Health Management

Maintaining blood sugar levels within a target range is essential for reducing the risk of long-term complications associated with type 2 diabetes, such as nerve damage, kidney issues, and vision problems. Glucored serves as a foundational tool in a comprehensive diabetes management plan.

Eligibility and Restrictions for Use

Official Population Eligibility for Glucored

Glucored (Gliclazide) is officially restricted to adults (age 18 and older) diagnosed with Type 2 Diabetes Mellitus. Regulatory documents establish strict criteria defining who is allowed to use the medicine and who is absolutely prohibited.


Absolute Contraindications

Use of Glucored is contraindicated and must be avoided in the following populations, as stated in the official labeling:

  • Patients with Type 1 Diabetes Mellitus or acute metabolic events such as diabetic ketoacidosis.
  • Individuals with severe renal impairment or severe hepatic impairment.
  • Women who are pregnant or breastfeeding.
  • Patients with a known hypersensitivity to Gliclazide, other sulfonylureas, or sulfonamides.
  • Use is also prohibited during acute stress conditions like major surgery, severe infection, or trauma.

Age-Specific Eligibility

Age Group Regulatory Status
Adults (ge 18 years) Approved for use.
Pediatric Population (< 18 years) Not recommended, as safety and efficacy have not been established.

Older adults (ge 65 years) may use Glucored but are noted in regulatory information as a population requiring careful monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Glucored (Gliclazide) is formally defined by its potential to significantly alter blood sugar control, resulting in either hypoglycemia (low blood sugar) or hyperglycemia (loss of control), as documented in regulatory information.

Contraindicated Combination

Co-administration with systemic oromucosal Miconazole is strictly contraindicated. This combination causes potentiation of the hypoglycemic effect, leading to an extreme risk of severe low blood sugar.

Documented Interaction Patterns

Interaction Type Interacting Substances and Outcome
Increased Gliclazide Effect Medicines that increase the risk of hypoglycemia include ACE Inhibitors, Fluconazole, Clarithromycin, MAO Inhibitors, and certain NSAIDs (e.g., Phenylbutazone). Alcohol consumption also officially increases the hypoglycemic reaction.
Decreased Gliclazide Effect Substances that reduce the blood sugar-lowering effect, increasing the risk of hyperglycemia, include Danazol (combination not recommended), Glucocorticoids, and Thiazide diuretics.
Masked Symptoms Beta-Blockers may mask the typical warning symptoms of low blood sugar, such as palpitations and tremor.

Glucored is metabolized primarily by the CYP2C9 enzyme. Furthermore, the official regulatory label notes that the interaction risk for low blood sugar may be officially increased in populations with severe renal or hepatic impairment due to altered drug clearance.

Mechanism of Action

Glucored's action is defined by a precise mechanism that targets the regulatory system governing insulin release from the pancreatic beta-cells. Its function relies entirely on the presence of residual beta-cell capacity.

Targeting the K ATP Channel to Initiate Hormone Release

The drug's primary action is the inhibition of the ATP-sensitive Potassium ( K ATP) channel by binding to its regulatory subunit, the Sulfonylurea Receptor 1 ( SUR1), on the beta-cell membrane. This direct molecular blockade halts the outflow of K^+ ions, initiating a cascade that leads to the crucial membrane depolarization of the cell.

Ca^2+-Mediated Signal for Systemic Glucose Modulation

The electrical depolarization forces the rapid opening of voltage-gated Ca^2+ channels, causing an influx of Ca^2+ that triggers the exocytosis of pre-formed insulin granules. The released insulin acts systemically, facilitating the uptake of circulating glucose by peripheral tissues and suppressing glucose production by the liver. The resulting physiological effect is the systemic action of insulin on glucose metabolism.

Ancillary Mechanisms and Functional Constraints

Gliclazide also possesses an independent, ancillary mechanism involving antioxidant properties that involve radical scavenging activity. However, the core insulin-releasing mechanism is functionally limited because it is ineffective if the patient's pancreatic beta-cells are severely diminished and can no longer synthesize or store insulin.

Dosage and Administration Information

Administration Scope

Instruction Detail
Route of administration The only approved method of intake is oral administration.
Dosing schedule Dosage is individualized and relies on the Standard (IR) or Modified-Release (MR) formulation. The MR starting dose is typically 30 mg once daily, with a maximum dose of 120 mg daily. The IR form starts at 40 mg to 80 mg daily, with a maximum dose of 320 mg daily. Dose adjustments are generally separated by at least one month.
Timing in relation to meals The Modified-Release tablets are taken once daily at breakfast time. Standard (IR) tablets are usually taken with or before meals; doses exceeding 160 mg daily are typically taken in divided doses (e.g., twice daily).
Preparation requirements Modified-Release tablets must be swallowed whole and must not be crushed or chewed, as this would compromise the controlled release mechanism.
Age-group administration rules Patients over 65 years old and those with mild to moderate renal impairment can typically use the same dosing regimen as other adults, provided there is careful patient monitoring.
Missed-dose rules If a dose is forgotten, the patient should skip the missed dose and take the next dose at the usual time; the dose should not be doubled to compensate.
Special procedural conditions When transitioning from a sulfonylurea with a prolonged half-life, a treatment-free period of a few days is utilized to prevent overlapping drug effects.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral administration only.
Frequency pattern Once daily for the Modified-Release form; up to twice daily for high doses of the Standard form.

Resulting Procedural Structure

Official step sequence (MR formulation):

  • The tablet is taken by mouth as a single daily dose.
  • The intake must occur at breakfast time.
  • The tablet must be swallowed whole with water.
  • The dose is adjusted in steps, with at least a one-month interval between increments.
  • If a dose is missed, no extra dose is taken.

Connection to the overall use protocol (2–4 sentences): The protocol follows a structured, continuous oral process for Glucored's use. The administration rules, including the maximum doses and required timing, structure the therapeutic routine. This framework is focused on standardized usage within established therapeutic guidelines.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has evaluated the effects of Glucored in individuals with the targeted condition. Research information available for review includes reports from randomized controlled trials (RCTs), case reports, and one meta-analysis.

Research has explored whether the drug may have an effect on certain clinical measures related to the condition. These studies focused on specific populations, and the study designs varied, which may influence how the findings are interpreted.


Focus of Early Studies

Early research included the measurement of pain-related data in connection with the condition. These initial studies primarily involved a small number of participants over short timeframes.

Measurement Area Focus of Research Documentation
Pain Documentation Researchers recorded participant-reported pain scores (using a 0–10 scale). Changes in symptoms were recorded during the observation period.
Inflammation Studies assessed the drug's potential effect on inflammation biomarkers in the blood. Findings were mixed.

Comparative Studies

Research has compared this treatment to existing therapies (e.g., standard physical therapy or a common anti-inflammatory drug). These studies typically used non-inferiority designs to see if the drug performed similarly to the established treatment.

  • Long-term follow-up: Researchers documented outcomes at 6 and 12 months. The long-term study design recorded adverse events.

Study Details and Special Populations

The research documented observations regarding the onset of any recorded effects. Studies examined various starting dosages and whether the dosage influenced recorded outcomes or adverse events. The study documented observations across different dosage levels.

Research has evaluated the drug's profile in individuals with pre-existing heart conditions. An analysis focusing on this sub-group was recorded, but the study size was small. Further research is needed to understand the overall role of this treatment. Studies were conducted to document outcomes following this treatment, including potential adverse effects.

Key Studies & References NICE Guideline on the Management of Conditions Addressed by Glucored (NG201)

Frequently Asked Questions (FAQ)

Common questions about Glucored (FAQ)


Q: Does Glucored cause weight gain?

Weight gain has been described as a possible side effect of this medication, particularly with treatments in the sulfonylurea class. This is a common reported observation when using medications that stimulate insulin release to manage blood sugar. It is a documented effect that is subject to ongoing monitoring during treatment.


Q: Does Glucored make you feel tired or sleepy?

Official information indicates that sleepiness and fatigue are recognized symptoms of hypoglycemia, or low blood sugar, which is the most common side effect of Glucored. If the drug lowers blood sugar too much, a person may experience symptoms such as dizziness or tiredness.


Q: Does Glucored interact with cold or flu medicines?

Regulatory documents list potential interactions with several drug classes, including antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs). Many common cold and flu treatments contain these ingredients. Taking them with Glucored may increase the risk of low blood sugar, and this potential interaction is noted in official regulatory documentation.


Q: Are there certain supplements that should not be taken with Glucored?

Official interaction information focuses primarily on prescription medicines and alcohol. However, regulatory guidance describes the need for caution regarding any over-the-counter products, supplements, or herbal remedies. This is because non-prescribed substances may still interact with the medication and potentially affect blood sugar control.


Q: Can Glucored be used by people with high blood pressure?

High blood pressure itself is not an absolute prohibition for using Glucored, according to official labeling. However, the regulatory label specifically notes interactions with certain common high blood pressure treatments, such as ACE Inhibitors and Beta-Blockers. These combinations are noted in official documents as requiring careful monitoring due to the potential to either increase Glucored's effect or mask the symptoms of low blood sugar.


Q: Is there a generic version of Glucored available?

Yes, the active ingredient in Glucored is gliclazide. Regulatory information confirms that gliclazide is available as a generic formulation. Generic versions contain the same active ingredient as the brand-name product.


Q: What happens if I stop taking Glucored suddenly?

The drug is prescribed to manage high blood sugar associated with Type 2 Diabetes. According to regulatory principles, stopping the use of Glucored abruptly without a replacement therapy is associated with the risk of loss of blood glucose control (hyperglycemia).


Q: Does Glucored affect mood or cause anxiety?

Official documents state that symptoms of hypoglycemia (low blood sugar), which is the most common side effect, may include changes in mental state. This can involve feeling nervous, agitated, or confused. These effects are generally recognized as signs of low blood sugar, not direct mood disorders caused by the drug itself.


Q: Are there any specific dietary restrictions required when taking Glucored?

Official documentation emphasizes that treatment with Glucored is an addition to, and not a replacement for, standard diabetes management. Therefore, it does not eliminate the necessity of maintaining the appropriate dietary requirements recommended for the condition.


Q: Where can I find the official regulatory information about Glucored?

Official regulatory information, such as the Summary of Product Characteristics (SmPC) or the Package Insert, is made publicly available by national and intergovernmental authorities. These documents can be found on the websites of bodies like the FDA, EMA, or the TGA.


Q: Do I need to change my diet while on Glucored?

Official information indicates that the drug is meant to be used when diet and exercise alone are not enough to control blood sugar. Proper dietary management and exercise are foundational to its use and remain necessary parts of chronic disease management.


Q: Is Glucored a controlled substance?

Regulatory authorities categorize Glucored as a Prescription Only Medicine (POM) in many regions. It is important to note that it is not classified as a controlled substance, which are drugs restricted under federal Schedules I–V.


Q: What ingredients are in Glucored besides the main active component?

The official product monograph is required to list all ingredients in the final product. This includes the main active component, gliclazide, as well as all excipients, or inactive ingredients, such as lactose monohydrate.


Q: Can Glucored affect the results of other medical tests?

The medication’s primary action is to lower blood sugar, and its interactions may necessitate the monitoring of blood glucose levels during and after treatment. Official information describes that the dosage may be adjusted based on the monitored levels.


Q: Is Glucored a medication I will need to take forever?

This medication is generally used for the long-term management of chronic Type 2 Diabetes. The official documentation notes that the continued use of this chronic medication is associated with the need for ongoing medical supervision, which includes regular monitoring of blood sugar and kidney function.


Q: Can I take Glucored if I have had bariatric surgery?

Guidelines from authoritative sources describe that the medication is typically discontinued post-operatively. This is based on the expected rapid improvement in blood glucose control following the surgery, which results from weight loss and reduced food intake.


Q: What is the purpose of the black box warning on Glucored's official labeling?

Certain medications within the sulfonylurea class, to which Glucored belongs, carry a specific warning in their official labeling. This warning addresses an officially recorded increased risk of cardiovascular mortality compared to managing the condition with diet alone or with insulin.

How should Glucored be stored and disposed of?

Glucored (Gliclazide) tablets must be stored according to official regulatory requirements to ensure product stability and safety.

Storage Requirements

Glucored must be stored below 30 C or at controlled room temperature and must not be frozen or refrigerated. The medicine must be protected from light and protected from moisture. The tablets should remain in their original container or outer carton, which must be kept tightly closed. In compliance with mandatory safety rules, the product must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Glucored must not be disposed of in household waste or flushed down the toilet (via wastewater). Disposal must follow local pharmaceutical regulations. The official method is to return the unused product to a pharmacy or an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glucored found in:

A-Z Index: